65PDHigh tumor mutational burden (TMB) and PD-L1 have similar predictive utility in 2L+ NSCLC patients (pts) treated with anti-PD-L1 and anti-CTLA-4. (23rd October 2018) - Higgs, B W; Morehouse, C A; Brohawn, P Z; Sridhar, S; Raja, R; Gao, G; Englert, J; Ranade, K